Akers Biosciences Announces Intention to Explore Strategic Alternatives to Maximize Shareholder Value

Akers Biosciences (NASDAQ:AKER) (AIM:AKR.L) a developer of rapid health information technologies, announces that the Board of Directors has initiated a process to evaluate strategic alternatives to maximize shareholder value.

As quoted in the press release:

 This process will consider a range of potential strategic alternatives including, but not limited to, business combinations, while simultaneously supporting the Company’s management and employees in the execution of the Company’s current business activities.

The Company does not plan to disclose or comment on developments regarding the strategic review process until it is complete or further disclosure is deemed appropriate. There can be no assurance that the exploration of strategic alternatives will result in any transaction or other alternative.

“The Board of Directors and management of the Company believes that now is the right time to review strategic alternatives to assess how best to maximize value for our shareholders. During this process, the team will remain focused on advancing our current business operations and serving our customers.”

Click here to read the full press release.